Table 5.
Pooled and Meta-Analysis for OS
| Parameter | Pooled Analysis (n = 441) |
Meta-Analysis (random effect; n = 247) |
||||||
|---|---|---|---|---|---|---|---|---|
| Univariable |
Multivariable |
Univariable |
Multivariable |
|||||
| Median (months; 95% CI) | P* | t | P† | Median (months; 95% CI) | P‡ | z | P§ | |
| Total studies | 9.4 (8.8 to 10.0) | 9.1 (8.6 to 9.6) | ||||||
| Personalized strategy | < .001 | 6.4 | < .001 | < .001 | 3.8 | < .001 | ||
| Yes | 15.9 (11.4 to 18.3) | 13.7 (11.1 to 16.4) | ||||||
| No | 9.0 (8.3 to 9.7) | 8.9 (8.3 to 9.3) | ||||||
| Chemotherapy status | .012 | 3.8 | < .001 | .575 | — | — | ||
| Chemotherapy naïve | 10.0 (9.3 to 12.0) | 9.4 (8.2 to 10.7) | ||||||
| Prior chemotherapy | 9.0 (9.2 to 9.7) | 9.0 (8.5 to 9.6) | ||||||
| Tumor type | .022 | 1.2 | .213 | .184 | — | — | ||
| Solid | 9.2 (8.5 to 9.8) | 9.0 (8.5 to 9.5) | ||||||
| Hematologic | 12.9 (8.7 to 16.5) | 11.3 (8.0 to 14.6) | ||||||
| Agent class | .611 | — | — | .458 | — | — | ||
| Cytotoxic | 9.4 (8.5 to 10.4) | 9.3 (8.5 to 10.1) | ||||||
| Targeted | 9.4 (8.5 to 10.1) | 8.9 (8.3 to 9.6) | ||||||
| Study design | .388 | — | — | .040 | 2.1 | .040 | ||
| Randomized | 8.8 (7.3 to 9.7) | 8.3 (7.1 to 9.4) | ||||||
| Nonrandomized | 9.7 (8.8 to 10.2) | 9.4 (8.8 to 9.9) | ||||||
| 5-Year impact factor | .487 | — | — | .129 | — | — | ||
| ≤ 10 | 9.4 (8.5 to 10.0) | 9.0 (8.4 to 9.5) | ||||||
| > 10 | 9.2 (8.1 to 10.5) | 10.1 (8.7 to 11.5) | ||||||
| No. of patients per arm | .003 | 1.3 | .201 | .0027 | 2.8 | .005 | ||
| ≤ 35 | 8.5 (7.6 to 9.8) | 8.3 (7.6 to 9.0) | ||||||
| > 35 | 9.9 (9.2 to 10.5) | 9.8 (9.1 to 10.5) | ||||||
| Administration route | .049 | 1.0 | .325 | .059 | — | — | ||
| Oral | 9.7 (8.8 to 10.5) | 9.6 (8.8 to 10.3) | ||||||
| Injection | 9.0 (8.0 to 10.0) | 8.6 (8.0 to 9.3) | ||||||
| FDA/EMA approval | .361 | — | — | .549 | — | — | ||
| No | 9.5 (7.8 to 10.0) | 8.8 (7.8 to 9.9) | ||||||
| Yes | 9.4 (8.8 to 10.4) | 9.2 (8.6 to 9.8) | ||||||
| No. of treating centers | .021 | 1.6 | .103 | < .001 | 1.3 | .187 | ||
| Single center | 8.3 (7.0 to 10.3) | 8.3 (7.3 to 9.3) | ||||||
| Multiple centers | 9.7 (8.8 to 10.0) | 9.2 (8.7 to 9.8) | ||||||
NOTE. Only variables that were significant in the univariable models were included in the multivariable analysis. The t and z values are used to compute the corresponding P values, and the higher they are, the more important they are for the multivariable model. The pooled analysis included 441 arms, and the meta-analysis included 247 arms for which median OS and the 95% CI values were available.
Abbreviations: EMA, European Medicines Agency; FDA, US Food and Drug Administration; OS, overall survival.
Wilcoxon test; the median in the univariable was not weighted.
Multiple linear regression model using a weighted least squares model.
Mixed effects analysis.
Random effects meta-regression model.
Cutoff value chosen to discriminate higher impact factor journals versus lower impact factor journals (sum of median and interquartile range).
Cutoff value used was the median of distribution.